Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Rapid and Sensitive Detection of Thrombospondin-2 Using Nanoparticle Sensors for Cancer Screening and Prognosis
Mohammadi, Maziyar Kalateh, Mirjalili, Seyedsina , Ikbal, Md Ashif , Xie, Hao , Wang, Chao , Xie, Hao , Mohammadi, Maziyar Kalateh

Mayo Clinic

Micromachines | March 20, 2025 | Volume: 16 | Issue: 3 | Pages: 354

10.3390/mi16030354 | PMID 40141965 Get It

Thrombospondin-2 (THBS2) is a prevailing prognostic biomarker implicated in different cancer types, such as deadly colorectal, pancreas, and triple-negative breast cancers. While the current methods for cancer-relevant protein detection, such as enzyme-linked immunosorbent assay (ELISA), mass spectrometry, and immunohistochemistry, are feasible at advanced stages, they have shortcomings in sensitivity, specificity, and accessibility, particularly at low concentrations in complex biological fluids for early detection. Here, we propose and demonstrate a modular, in-solution assay design concept, Nanoparticle-Supported Rapid Electronic Detection (NasRED), as a versatile cancer screening and diagnostic platform. NasRED utilizes antibody-functionalized gold nanoparticles (AuNPs) to capture target proteins from a minute amount of sample (<10 µL) and achieve optimal performance with a short assay time by introducing active fluidic forces that act to promote biochemical reaction and accelerate signal transduction. This rapid (15 min) process serves to form AuNP clusters upon THBS2 binding and subsequently precipitate such clusters, resulting in color modulation of the test tubes that is dependent on the THBS2 concentration. Finally, a semiconductor-based, portable electronic device is used to digitize the optical signals for the sensitive detection of THBS2. High sensitivity (femtomolar level) and a large dynamic range (five orders of magnitude) are obtained to analyze THBS2 spiked in PBS, serum, whole blood, saliva, cerebrospinal fluids, and synovial fluids. High specificity is also preserved in differentiating THBS2 from other markers such as cancer antigen (CA) 19-9 and bovine serum albumin (BSA). This study highlights NasRED’s potential to enhance cancer prognosis and screening by offering a cost-effective, accessible, and minimally invasive solution.
Single-cell multiomics reveals disrupted glial gene regulatory programs in Alzheimer’s disease via interpretable machine learning
Zhang, Shuwen , Hu, Hongru , Wang, Xue , Chengjie, Xiong, Asmann, Yan W. , Ren, Yingxue , Zhang, Shuwen , Zhang, Shuwen

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.14.643349 | PMID 40166228 Get It

ABSTRACT Recent development of single-cell technology across multiple omics platforms has provided new ways to obtain holistic views of cells to study disease pathobiology. Alzheimer’s disease (AD) is the most common form of dementia worldwide, yet the detailed understanding of its cellular and molecular mechanisms remains limited. In this study, we analyzed paired single-cell transcriptomic (scRNA-seq) and chromatin accessibility (scATAC-seq) data from the Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) Consortium to investigate the molecular mechanisms of AD at a cell-subpopulation-specific resolution focusing on glial cells. We benchmarked various multi-omics integration methods using diverse metrics and built an analytic workflow that enabled effective batch correction and cross-modality alignment, creating a unified cell state space. Through integrative analysis of 26 human brain samples, we uncovered AD-associated gene expression and pathway changes in glial subpopulations and highlighted important transcriptomic and epigenomic signatures via functional inference and interpretable machine learning paradigms, discovering the profound involvement of the Solute Carrier proteins (SLC) family genes in multiple glial cell types. We also identified glial cell-specific regulatory programs mediated by key transcription factors such as JUN and FOSL2 in astrocytes, the Zinc Finger (ZNF) family genes in microglia, and the SOX family of transcription factors in oligodendrocytes. Our study provides a comprehensive workflow and a high-resolution view of how glial regulatory programs are disrupted in AD. Our findings offer novel insights into disease-related changes in gene regulation and suggest potential targets for further research and therapy.
Outcome of Goniotomy Over 120, 240 and 360 Degrees in Juvenile Open Angle Glaucoma: A Multicenter Study
Wang, Zhixuan , Fan, Hanying, Ge, Qingshu, Dang, Guangfu , Yang, Xiao , Xie, Lin , Zhu, Xiaoming , Yang, Yangfan , Wang, Yuhong , Liu, Jinkun , Zhang, Hongyang , Feng, Yuhan, Qi, Yongjun , Ye, Xiangxiang, Lai, Mingying , Lin, Peijie , Wang, Pusheng, Han, Shumei, Xu, Jiangang , Tao, Liming, Liu, Heting , Nie, Xin , Liao, Mengfei, Zou, Kai , Song, Yunhe , Lin, Fengbin , Xiaokaiti, Dilimulati, Liu, Xiaoyi , Fang, Zige , Jin, Ling, Chen, Yu , Han, Ying , Zeng, Liuzhi , Tham, Clement C, Yang, Zefeng , Ye, Xiangxiang, Lin, Peijie , Wang, Pusheng, Han, Shumei, Nie, Xin, Zou, Kai, Jiang, Yi , Zhou, Fengqi , Tham, Clement Chee Yung , Pan, Xiaojing , Weinreb, Robert Neal , Zhang, Xiulan

Mayo Clinic

Journal of Glaucoma | March 19, 2025 | Volume: 34 | Issue: 6 | Pages: 433-439

10.1097/ijg.0000000000002569 | PMID 40105411 Get It

Précis: 240-degree and 360-degree goniotomy (GT) demonstrated similar efficacy in intraocular pressure (IOP) reduction, both outperforming 120-degree GT in patients with juvenile open angle glaucoma (JOAG) at postoperative 6-month follow-up. Objective: To compare the surgical efficacy and safety of 120-degree, 240-degree, and 360-degree GT for patients with JOAG. Patients and Methods: This multicenter retrospective study included 102 eyes of 102 patients with JOAG, who underwent GT with a follow-up of at least 6 months. Patients were categorized into 3 groups: (1) 120-degree GT, (2) 240-degree GT, and (3) 360-degree GT. IOP, glaucoma medications, and complications were recorded at baseline and the final visit. Complete success and qualified success were defined as a postoperative IOP ≤21 mm Hg without and with medications, respectively. Results: Mean age of the participants was 24.4 ± 7.9 years. After a mean follow-up of 8.1 ± 2.7 months, complete success rates were similar between the 240-degree GT (45.2%) and the 360-degree GT (63.2%; P = 0.135), and both were superior to 120-degree GT (18.2%; P < 0.05). Qualified success rates among patients in the 120-degree, 240-degree, and 360-degree GT groups were 93.9%, 96.8%, and 100%, respectively, and showed no statistically significant difference (P = 0.292). 360-degree GT required fewer medications than 240-degree GT and 120-degree GT (P < 0.05), with no significant difference in medications between 120-degree GT and 240-degree GT (P > 0.05). Hyphema was the most common postoperative complication, with a significantly higher incidence in the 360-degree GT (68.4%) compared with the 240-degree GT (41.9%) and 120-degree GT (33.3%; P < 0.05). Conclusions: 240-degree and 360-degree GT showed similar efficacy in IOP reduction and were superior to 120-degree GT. More extensive GT may provide better outcomes in JOAG.
Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett’s esophagus-related neoplasia
Joseph, Abel , Vantanasiri, Kornpong , Garg, Nikita , Codipilly, Don C. , Wang, Kenneth T. , Harmsen, William S. , Jang, Sunguk, Iyer, Prasad G. , Bhatt, Amit, Bhatt, Amit , Leggett, Cadman, Iyer, Prasad, Bhatt, Amit , Goyal, Rohit, Leggett, Cadman L. , Vargo, John Joseph

Mayo Clinic

Endoscopy International Open | March 18, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2422-2815 | PMID 40376017 Get It

AbstractAlthough endoscopic submucosal dissection (ESD) is associated with higher en-bloc and R0 resection rates than cap-assisted endoscopic mucosal resection (cEMR), its comparative impact on achieving complete remission of dysplasia (CRD) and intestinal metaplasia (CRIM) in BE endoscopic eradication therapy (EET) is not well defined. We aimed to compare the journey of patients from initial endoscopic resection (ER) with ESD and cEMR to achieving CRD and CRIM.Patients undergoing ESD or cEMR followed by ablation for BE neoplasia at two academic institutions in the United States were included. Primary outcomes included CRD and CRIM rates following ER in the two groups. Secondary outcomes included the number of resection/ablative procedures from initial ER to achieving CRD and CRIM. Inverse probability treatment weighting (IPTW) was used to balance confounding variables between groups.A total of 801 patients (606 cEMR, 195 ESD) were included. ESD group patients had higher en-bloc resection rates (ESD 94.4%, cEMR 44.7%). Higher rates of CRD were observed in patients undergoing initial ESD (HR 1.53, P < 0.01). With time-to-event and IPTW analyses, rates of achieving CRD and CRIM were comparable between the groups. There were no significant differences in mean number of endoscopic resection or ablative procedures among patients undergoing initial cEMR resection compared with those treated with initial ESD.Despite larger lesion sizes and more cancers in patients undergoing ESD, the EET journey to achieving CRD and CRIM was comparable to that in patients receiving cEMR. Prospective studies are required to further study differences between these two treatment approaches.
RBAD: A Dataset and Benchmark for Retinal Vessels Branching Angle Detection
Zhu, Wenhui , Qin, Jiayou, Li, Xin , Dumitrașcu, Oana , Chen, Xiwen , Razi, Abolfazl , Wang, Hao Henry , Qiu, Peijie , Wang, Yalin

Mayo Clinic

2024 IEEE EMBS International Conference on Biomedical and Health Informatics (BHI) | March 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1109/bhi62660.2024.10913865 | PMID 40356674 Get It

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents
Neil, Elizabeth , Bruhnding, Aubree , Ahmed, Zubair , Kumthekar, Priya , Blondin, Nicholas, Patel, Chirag B, Hsu, Sigmund, Wang, Feng , Rosen, Noah , Burish, Mark J. , Corbin, Zachary , Patel, Chirag B. , Neil, Elizabeth C , Kumthekar, Priya , Grommes, Christian , Patel, Chirag B, Miao, Hongyu , Singh, Rashmi B. Halker

Mayo Clinic

Neuro-Oncology Practice | March 17, 2025 | Volume: 12 | Issue: 6 | Pages: 1121-1129

10.1093/nop/npaf033 | PMID 41458932 Get It

Abstract Background Neuro-oncology education in American neurology departments is highly variable, with no clear guidelines on appropriate practices. To better understand its current state, we focus on the perspective of departmental Grand Rounds (GR), views of adult neurology residency program directors (ANRPD), neuro-oncologists, and residents. Methods First, we obtained GR series from academic years 2017–2018 and 2018–2019 via an online search and direct emails to neurology residency programs. Second, two online surveys were dispensed to ANRPD and neuro-oncologists. Third, a cohort of neurology residents completed surveys with pre/post-didactic tests. Results Neuro-oncology consisted of 7% (28/ 411) GR in 2017–2018 and 6% (29/463) in 2018–2019; approximately 20% of institutions had no neuro-oncology GR. Twenty neuro-oncologists and 25 of the 175 ANRPDs completed the surveys. Respondents thought 1-to-4 GR annually was adequate. Thirty-five residents completed the survey. Residents might consider neuro-oncology with more exposure (77%, 27/35) and a stronger knowledge base (57%, 20/35). After 8-hours of didactics, residents demonstrated significant (P = .019) pre-/post-test improvement. Conclusions Here, we begin to define the status of several aspects of neuro-oncology education: 1 in 5 academic institutions do not have any neuro-oncology GR lectures annually, and both ANRPDs and neuro-oncologists agree that 1-to-4 lectures annually are adequate. Residents overwhelmingly stated they would be more interested in neuro-oncology with more exposure, and a pilot study of 8 hours of didactic did show knowledge improvement. While these initial datasets require confirmation in larger studies, it suggests that small changes to the current state at some institutions could have a meaningful impact.
Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
Chung, Leland W.K. , Steen, Virginia , Furst, Daniel E. , Castelino, Flavia V. , Trojanowski, Marcin A. , Domsic, Robyn T. , Katsumoto, Tamiko R. , Goulaouic, Hélène , Wang, Hong , Espinasse, Melanie, El‐Chemaly, Souheil , Wang, Rui , Chung, Lorinda , Furst, Daniel E , Domsic, Robyn T , Katsumoto, Tamiko R , Wang, Rui , Silver, Richard M. , Spiera, Robert , Rodríguez-Pla, Alicia

Mayo Clinic

Rheumatology | March 15, 2025 | Volume: 64 | Issue: 7 | Pages: 4299-4308

10.1093/rheumatology/keaf062 | PMID 40088930 Get It

Abstract Objectives To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies. Methods Eligible patients were randomised 1:1:1 to receive belumosudil 200 mg once daily (QD) or twice daily (BID), or placebo for 28 weeks (double-blind period). After unblinding, the patients who received belumosudil continued the same dose, whereas the patients who received placebo were re-randomised for one of the belumosudil doses for 24 weeks (open-label extension). Results Thirty-five and 31 patients were treated in the double-blind and open-label periods, respectively. The study was terminated prematurely, and target enrolment was not met. The primary end point, of CRISS score ≥0.60 at week 24, did not exhibit an efficacy signal in the belumosudil vs placebo groups [odds ratio: 1.06 (0.19–5.82; P = 0.9472) for the QD, and 0.39 (0.07–2.35; P = 0.3078) for the BID group]. Belumosudil was well tolerated and exhibited similar safety profiles in both double-blind and open-label periods. Tissue-based RNA sequencing analysis revealed FOXP3 upregulation and STAT3, IL23A and TGF-β downregulation in patients with CRISS score ≥0.60, which supported the mechanism of action of belumosudil. In blood and tissue samples, trends of decreased fibrosis biomarker levels were seen in the belumosudil-treated group vs placebo. Conclusion Efficacy signal for belumosudil could not be detected. Signalling pathway modulation analysis supported the mechanism of action of belumosudil. A trend for decreased fibrosis-related biomarkers was observed in the belumosudil-treated group. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT03919799.
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku, Oladapo , Tan, Winston , Patnaik, Amita , LoRusso, Patricia , Richardson, Debra L. , Naqash, Abdul Rafeh , Lynam, Sarah , Kyriakopoulos, Christos E. , Dowlati, Afshin , Chamberlain, Marc C. , Yeku, Oladapo O , Tan, Winston W., Richardson, Debra L , Kyriakopoulos, Christos E , Naqash, Abdul Rafeh , Barve, Minal , Wang, Judy , Fu, Siqing , Gordon, Michael S. , Hubbard, Joleen M. , Kummar, Shivaani , Winer, Ira Seth

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 13, 2025 | Volume: 13 | Issue: 3 | Pages: e010959

10.1136/jitc-2024-010959 | PMID 40081941 Get It

Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC. Methods PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg or PY314 10 mg/kg), based on the recommended dose for expansion derived from the phase 1a studies. At the time of first progression, patients could continue study drug and crossover to combination therapy with pembrolizumab (200 mg) every 3 weeks at the discretion of the investigator. Disease assessment by Response Evaluation Criteria in Solid Tumor version 1.1 was performed every 6 weeks. Results 17 patients were enrolled in the PY159 study (median age 67, range 22–77; median prior therapies 6, range 2–18) and 16 patients in PY314 (median age 65.5, range 49–81; median prior therapies 4, range 2–10). 7 patients in PY159 and 8 patients in PY314 crossed over to combination therapy. Safety events included the following: treatment-related adverse events occurred in 15 patients (88.2%) in PY159 and 9 patients (56.3%) in PY314. Infusion-related reactions occurred in 6 patients (35.3%) in PY159 and 3 patients (18.8%) in PY314. Immune-related adverse events occurred in 13 patients (76.5%) in PY159 (arthralgias) and 1 patient (6.3%) in PY314 (diarrhea). Serious adverse events occurred in 6 patients (36.3%) in PY159 (1 related) and 12 patients (75%) in PY314 (all unrelated). The best radiographic response in PY159 was stable disease in 8/16 patients (50%; median 16 weeks, range 9–33), and in PY314, it was stable disease in 8/16 patients (50%; median 12 weeks, range 6–36). Median PFS was 2.76 months and 2.69 months in PY159 and PY314, respectively. There were no responses in the crossover arm. Conclusions Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.
Resident Wellness: AJR Podcast Series on Wellness, Episode 12
Wang, Sherry S. , Wen, Jessica T.

Mayo Clinic

American Journal of Roentgenology | March 12, 2025 | Volume: 224 | Issue: 5 | Pages: No page available

10.2214/ajr.25.32901 | PMID 40071903 Get It

Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Gajjar, Amar , Mahajan, Anita , Canan, Liz, Chi, Susan , Cluster, Andrew , Cole, Bonnie , Darlington, Wendy , Dorris, Kathleen , Elster, Jennifer , Franson, Andrea , Helgager, Jeffrey, Lin, Chi , Metrock, Laura, Nanda, Ronica H. , Partap, Sonia , Plant, Ashley , Reynolds, Renée M. , Stearns, Duncan , Storm, Phillip, Wang, Leo D. , Whipple, Nicholas , Zaky, Wafik , McMillian, Nicole R., Ramakrishnan, Swathi , Franson, Andrea , Bale, Tejus , Bowers, Daniel C. , Cohen, Kenneth J. , Coven, Scott L. , Ermoian, Ralph P. , George, Elizabeth , Landi, Daniel B. , Palmer, Joshua D. , Pruthi, Sumit , Wang, Anthony

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 113-130

10.6004/jnccn.2025.0012 | PMID 40073837 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents. This article summarizes the studies and panel discussion that serve as the rationale for comprehensive care recommendations included in the NCCN Guidelines for Pediatric Central Nervous System Cancers.